1. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.

    JAMA Neurology 73(6):721 (2016) PMID 27088965

    The use of anticholinergic (AC) medication is linked to cognitive impairment and an increased risk of dementia. To our knowledge, this is the first study to investigate the association between AC medication use and neuroimaging biomarkers of brain metabolism and atrophy as a proxy for understand...
  2. Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial.

    Neurology 86(22):2071 (2016) PMID 27164691 PMCID PMC4891209

    To determine whether vitamin E would slow the progression of cognitive deterioration and dementia in aging persons with Down syndrome (DS). A randomized, double-blind controlled clinical trial was conducted at 21 clinical sites, and researchers trained in research procedures recruited adults wit...
  3. Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.

    Neurology 86(20):1887 (2016) PMID 27164667 PMCID PMC4873684

    To estimate points along the spectrum of β-amyloid pathology at which rates of change of several measures of neuronal injury and cognitive decline begin to accelerate. In 460 patients with mild cognitive impairment (MCI), we estimated the points at which rates of florbetapir PET, fluorodeoxygluc...
  4. Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials.

    Alzheimer's & Dementia 12(5):598 (2016) PMID 26917500

    Accurate estimates of cognitive and clinical decline rates are essential to the design of clinical trials in Alzheimer's disease (AD) dementia. To investigate the trajectories of individuals enrolled in therapeutic trials in mild-to-moderate AD, we analyzed the placebo arm data from 20 clinical ...
  5. Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials.

    Alzheimer's & Dementia 12(5):631 (2016) PMID 27157073

  6. Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia.

    American Journal of Geriatric Psychiatry 24(2):126 (2016) PMID 26238228 PMCID PMC4973623

    Investigate the association of chronic depressive symptomatology (chrDS) with cortical atrophy rates and conversion to Alzheimer dementia (AD) over 3 years in mild cognitive impairment (MCI). In a multicenter, clinic-based study, MCI elderly participants were selected from the Alzheimer's Diseas...
  7. Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease.

    BMC Medical Genomics 9 Suppl 1:30 (2016) PMID 27535542

    Pathogenic mutations in PSEN1 are known to cause familial early-onset Alzheimer's disease (EOAD) but common variants in PSEN1 have not been found to strongly influence late-onset AD (LOAD). The association of rare variants in PSEN1 with LOAD-related endophenotypes has received little attention. ...
    PDF not found
  8. CAP--advancing the evaluation of preclinical Alzheimer disease treatments.

    Nature Clinical Practice Neurology 12(1):56 (2016) PMID 26416539 PMCID PMC4847536

    If we are to find treatments to postpone, reduce the risk of, or completely prevent the clinical onset of Alzheimer disease (AD), we need faster methods to evaluate promising preclinical AD treatments, new ways to work together in support of common goals, and a determination to expedite the init...
  9. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.

    Alzheimer's Research & Therapy 8:25 (2016) PMID 27358067 PMCID PMC4928349

    Apolipoprotein E (APOE) ɛ4 and low cerebrospinal fluid (CSF) amyloid-β42 (Aβ42) levels are predictors for developing Alzheimer's disease (AD). The results of several studies indicate an interaction between docosahexaenoic acid (DHA) consumption and cognitive outcomes by APOE genotype. Our object...
  10. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern.

    Alzheimer's & Dementia 11(12):1417 (2015) PMID 25960448 PMCID PMC4637003

    This study assessed apolipoprotein E (APOE) ε4 carrier status effects on Alzheimer's disease imaging and cerebrospinal fluid (CSF) biomarkers in cognitively normal older adults with significant memory concerns (SMC). Cognitively normal, SMC, and early mild cognitive impairment participants from ...
  11. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.

    Neurology 85(16):1383 (2015) PMID 26362286 PMCID PMC4626244

    A randomized, placebo-controlled, double-blind, multicenter 52-week phase 2 trial of resveratrol in individuals with mild to moderate Alzheimer disease (AD) examined its safety and tolerability and effects on biomarker (plasma Aβ40 and Aβ42, CSF Aβ40, Aβ42, tau, and phospho-tau 181) and volumetr...
  12. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP.

    Brain 138(Pt 10):3076 (2015) PMID 26268530 PMCID PMC4671479

    Brain amyloid deposition is thought to be a seminal event in Alzheimer's disease. To identify genes influencing Alzheimer's disease pathogenesis, we performed a genome-wide association study of longitudinal change in brain amyloid burden measured by (18)F-florbetapir PET. A novel association wit...
  13. The transitional association between β-amyloid pathology and regional brain atrophy.

    Alzheimer's & Dementia 11(10):1171 (2015) PMID 25499535 PMCID PMC4461550

    Alzheimer's disease (AD) is characterized by the accumulation of β-amyloid (Aβ) associated with brain atrophy and cognitive decline. The functional form to model the association between Aβ and regional brain atrophy has not been well defined. To determine the relationship between Aβ and atrophy,...
  14. Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.

    Journal of Alzheimer's Disease 48 Suppl 1:S171 (2015) PMID 26402088

    There is evolving evidence that individuals categorized with subjective cognitive decline (SCD) are potentially at higher risk for developing objective and progressive cognitive impairment compared to cognitively healthy individuals without apparent subjective complaints. Interestingly, SCD, dur...
  15. Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials.

    Alzheimer's & Dementia 11(9):1069 (2015) PMID 25301682 PMCID PMC4387108

    Little is known about the utility of plasma amyloid beta (Aβ) in clinical trials of Alzheimer's disease (AD). We analyzed longitudinal plasma samples from two large multicenter clinical trials: (1) donezepil and vitamin E in mild cognitive impairment (n = 405, 24 months) and (2) simvastatin in m...
  16. Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease.

    Alzheimer's & Dementia 11(9):1080 (2015) PMID 25449531 PMCID PMC4433437

    It is recognized that individuals with mild cognitive impairment (MCI) already demonstrate difficulty in aspects of daily functioning, which predicts disease progression. This study examined the relationship between self- versus informant-report of functional ability, and how those reports relat...
  17. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions.

    The Lancet Neurology 14(9):926 (2015) PMID 26213339

    Interventions that have even quite modest effects at the individual level could drastically reduce the future burden of dementia associated with Alzheimer's disease at the population level. In the past three decades, both pharmacological and lifestyle interventions have been studied for the prev...
  18. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.

    Alzheimer's & Dementia 11(7):772 (2015) PMID 26194312

    We describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1-42), t-tau, and p-tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and i...
  19. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.

    Alzheimer's & Dementia 11(7):865 (2015) PMID 26194320 PMCID PMC4659407

    The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. We searched for ADNI publications using established methods. ADNI has (1) developed s...
  20. Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans.

    Alzheimer's & Dementia 11(7):734 (2015) PMID 26194309 PMCID PMC4643840

    This article reviews the current status of the Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI), and summarizes planning for the next stage of the project. Clinical Core activities and plans were synthesized based on discussions among the Core leaders and external advisors...